NCT07206849View on ClinicalTrials.gov

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

March 1, 2030

Study Completion Date

March 1, 2037

Conditions
High Grade Glioma (HGG) of the Brain With BRAF AberrationHigh Grade Glioma (III or IV)Diffuse Intrinsic Pontine GliomaHigh Grade GliomaWHO Grade 3 GliomaWHO Grade 4 GliomaMetastatic Brain Tumor
Interventions
DRUG

Tovorafenib

Tovorafenib will be given orally once weekly (QW) throughout each cycle.

All Listed Sponsors
lead

Nationwide Children's Hospital

OTHER